Accolade (NASDAQ:ACCD) Posts Earnings Results, Beats Estimates By $0.01 EPS

Accolade (NASDAQ:ACCD) announced its quarterly earnings data on Thursday. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.01, Briefing.com reports. Accolade had a negative net margin of 24.09% and a negative return on equity of 22.57%. The firm had revenue of $124.80 million during the quarter, compared to analysts’ expectations of $123.91 million. During the same quarter last year, the business earned ($0.42) earnings per share. The business’s revenue for the quarter was up 26.1% compared to the same quarter last year. Accolade updated its FY 2025 guidance to EPS and its Q1 2025 guidance to EPS.

Accolade Stock Down 14.1 %

NASDAQ ACCD traded down $1.30 during trading hours on Friday, hitting $7.89. The company had a trading volume of 1,491,193 shares, compared to its average volume of 585,879. The firm’s 50 day moving average is $9.66 and its 200 day moving average is $9.91. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.35 and a quick ratio of 2.35. Accolade has a fifty-two week low of $6.33 and a fifty-two week high of $17.00. The company has a market capitalization of $610.76 million, a price-to-earnings ratio of -5.93 and a beta of 2.08.

Wall Street Analyst Weigh In

ACCD has been the subject of a number of research reports. SVB Leerink began coverage on shares of Accolade in a research report on Monday, February 26th. They set an “outperform” rating and a $16.00 price target for the company. Stifel Nicolaus lowered their target price on Accolade from $15.00 to $13.00 and set a “buy” rating on the stock in a report on Monday, April 22nd. Canaccord Genuity Group cut their price target on Accolade from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday. Wells Fargo & Company increased their price objective on shares of Accolade from $10.00 to $12.00 and gave the company an “equal weight” rating in a research note on Tuesday, January 9th. Finally, Piper Sandler increased their price objective on shares of Accolade from $12.00 to $15.00 and gave the company an “overweight” rating in a research note on Tuesday, January 9th. Four investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $14.80.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.